Loading...
NPI 1851361778 · Charleston, SC · General Acute Care Hospital
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Bon Secours St. Francis Xavier Hospital Inc. is a general acute care hospital provider located in Charleston, South Carolina. This profile covers 0 Medicare and 282 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Bon Secours St. Francis Xavier Hospital Inc. |
| Address | 2095 Henry Tecklenburg Dr |
| City | Charleston |
| State | SC |
| ZIP | 29414 |
| Taxonomy | General Acute Care Hospital |
| NPI Enumerated | January 24, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $35.9M |
| Medicare | $0 |
This provider has no Medicare billing on file and reports $35.9M in lifetime Medicaid revenue, which makes its reported business effectively single-payer Medicaid in our dataset; absence of Medicare activity should be treated as a material characteristic when modeling payer risk and revenue diversification. The lack of Medicare claims limits cross-payer comparators and means payer negotiation dynamics and patient mix will be driven primarily by Medicaid policy and managed-Medicaid relationships.
Revenue is concentrated in a small set of infusion and injection-related codes: the precomputed top three Medicaid codes (J7050, 96372, 96413) account for 34.8% of the provider's total Medicaid revenue, with J7050 alone at $4.4M (15.1%), 96372 at $3M (10.2%), and 96413 at $2.8M (9.6%). This concentration indicates a reliance on high-cost drug/infusion billing for a significant portion of Medicaid dollars and should be a focus for financial forecasting and contract discussions.
The code mix points to a sizable infusion/oncology and outpatient procedure footprint: J7050 (normal saline infusion), 96372 (therapeutic/prophylactic injections), and 96413 (chemotherapy administration) are the top revenue drivers, suggesting the hospital operates an active infusion/chemotherapy service line and supports serial medication administration workflows. Ancillary codes such as 96374, 96365, 96375, 96360, and 96361 further reinforce a workflow centered on IV pushes, infusions, and fluid/electrolyte management consistent with an oncology/infusion center and acute care infusion throughput.
Beyond infusion and chemotherapy, the provider shows high volumes across core acute-care services: laboratory panels and phlebotomy are large claim drivers (80053: 29.9K claims, $2M revenue; 80048: 17.2K claims, $1M revenue; 36415: 22.5K claims, $1.8M revenue) and multiple ED E/M codes appear in the top list (99283: 27.3K claims, $1.6M; 99284 and 99282 also present). Obstetric imaging is also meaningful (76816 $691.6K; 76811 $653.1K; 76819 $553.1K), indicating the hospital operates broad inpatient and outpatient acute-care services including labor/delivery and standard emergency/lab operations.
Competitive standing is mixed: for key infusion/chemotherapy codes the provider ranks relatively high in-state but is not a statewide outlier — 96413 ranks #8 of 51 (86th percentile) indicating above-average chemotherapy volume, while 96372 ranks #41 of 409 (90th percentile) reflecting strong injection service volume relative to many peers; J7050 ranks #11 of 52 (80th percentile), a solid but not dominant position. At the same time, several large-volume codes are described as "typical, unremarkable volume," which signals the hospital is an important regional player for specific service lines rather than an undisputed statewide leader across all categories.
A couple of codes stand out as statistical high outliers by the supplied labels: 81003 (urinalysis via automated reader) is flagged at the 95th percentile and described as "notably above typical state volume," and 96375 (sequential IV push infusions) is at the 93th percentile and also "notably above typical state volume." These labeled outlier signals point to particularly high throughput in certain lab and infusion procedures and merit further operational review to understand capacity, staffing, and supply constraints driving those volumes.
Advanced imaging capability is evident but moderately scaled: A9552 (FDG PET) generates $929.9K (3.2% of Medicaid revenue) and ranks #6 of 16 (67th percentile), indicating onsite PET services at a modest in-state standing, and CT of the abdomen/pelvis (74177) contributes $294.4K (1.0%). Together these suggest the hospital supports higher-acuity diagnostic services without being a top-volume imaging hub statewide.
The provider's NPI was enumerated on 2006-01-24 (~20 years ago), indicating a long-standing presence in the market; combined with the breadth of codes across ED, obstetrics, lab, infusion, chemotherapy, and imaging, this tenure is consistent with an established general acute care hospital operating multiple core service lines and sustaining steady Medicaid-revenue streams.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
282 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J7050 | Infusion, normal saline solution, 250 cc | 4,070 | $1,080 | $4.4M |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 10,180 | $290 | $3M |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 6,580 | $430 | $2.8M |
| J3490 | Unclassified drugs | 2,070 | $1,290 | $2.7M |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 29,920 | $70 | $2M |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 22,480 | $80 | $1.8M |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 27,280 | $60 | $1.6M |
| 96374 | The provider administers a single medication or other substance rapidly into a vein to treat, prevent, or diagnose a condition. | 14,990 | $80 | $1.1M |
| 80048 | The lab analyst performs a basic metabolic pane (BMP) test in which he measures the blood level of eight chemicals including total calcium, sodium, potassium, chloride, carbon dioxide, glucose, blood… | 17,230 | $60 | $1M |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 500 | $1,850 | $929.9K |
Showing 1–10 of 282
How this provider's Medicaid billing volume and revenue compare to other South Carolina providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. South Carolina median
282 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 6 | 20 | 350 | $1,170 | $776.4K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 24 | 210 | 1,470 | $60 | $615K |
| 97530 | The provider uses various activities during direct contact with the patient to improve the patient’s functional performance. Use this code for each 15 minutes of activity. | 253 | 350 | 2,590 | $70 | $550.2K |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 42 | 340 | 110 | $40 | $450.5K |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 38 | 350 | 100 | $50 | $446.9K |
| 99285 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a high level of medical decision making. | 40 | 200 | 1,680 | $50 | $443.2K |
| 70553 | In this procedure, the provider performs a magnetic resonance imaging, or MRI, study of the brain including the brain stem. He performs this procedure without using contrast material. He then follows… | 30 | 60 | 170 | $430 | $434.9K |
| 99282 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a straightforward level of medical decision making. | 47 | 140 | 2,520 | $90 | $415.3K |
| 97110 | Therapeutic exercise is a form of physical therapy that utilizes specially designed exercises and activities to help patients gain better mobility and fitness levels. Normally used on patients with… | 73 | 290 | 2,600 | $60 | $414.4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 32 | 110 | 1,880 | $100 | $414K |
Showing 1–10 of 282
Other providers in the same ZIP code as Bon Secours St. Francis Xavier Hospital Inc., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.